Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Kyowa Kirin/Sandoz’s Rituxan Biosimilar Expands Label
November 19, 2020
- Half of Patients Postpone or Cancel Regular Checkups amid COVID-19: Roche Survey
November 19, 2020
- Number of Patients Treated by Pediatricians Shows Sharp Rebound in October: Survey
November 19, 2020
- 20% of Osteoporosis Patients Reduce/Halt Clinic Visits Amid COVID-19 Pandemic: Survey
November 19, 2020
- Daiichi Sankyo, CureApp Link Up on Cancer Treatment Support App, Eye Clinical Study in FY2021
November 19, 2020
- Nichi-Iko Files Avastin Biosimilar in Japan
November 19, 2020
- As Pfizer/Mylan’s Generics Merger Closed, 4 Viatris Group Firms to Operate Together in Japan
November 18, 2020
- Japan Pharma Market Shrivels 5.1% on COVID-19 Crisis in July-Sept.: IQVIA
November 18, 2020
- Eisai’s Fycompa Gets Pediatric Nod in Europe
November 17, 2020
- Janssen Resumes Japan PI for COVID-19 Vaccine after Temporary Pause
November 17, 2020
- Shionogi Forms Consortium with Univ. of Cambridge, AZ for Digitalized Chemical Synthesis
November 17, 2020
- Medicago, GSK Commence PII of Adjuvanted COVID-19 Vaccine, Progressing into PIII during December
November 17, 2020
- Otsuka’s Pharma Sales Grow 6.3% in January-September on Global Brands
November 16, 2020
- Some Hospitals Shun New Nichi-Iko Generics after Massive Recalls, President Reveals
November 13, 2020
- Generic Makers Seeking to Invalidate Feburic Patent, Can They Get Full Indications?
November 13, 2020
- Fuji Pharma, M3 Join Hands on Dysmenorrhea Med in Japan
November 13, 2020
- Voluntary Recalls Launched for Pfizer/MSD’s Antidepressant Trazodone
November 13, 2020
- Sagent Launches US PII to Test Camostat Mesilate for COVID-19
November 13, 2020
- Humira’s Pediatric Dosage Filed for Ulcerative Colitis in Japan: AbbVie
November 13, 2020
- Osaka Univ. Spin-Off Boots Up to Develop First Treatment for Skeletal Muscle Damage, Atrophy
November 13, 2020
ページ
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…